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Available online 8 August 2014Abstract Background: Diabetes mellitus is a rapidly growing disease world-wide that is estimated
to be present in 6.6% of the international population and projected to be increased by 7.8% in 2030.
Treating diabetic patients is multifaceted in all aspects and they require objectives and optimum
information in order to obtain the maximum beneﬁts of their treatment and avoid complications.
Pharmacists are increasingly considered as a part of the health care system. Hence, the aim of this
review is to address and summarize the effectiveness of clinical pharmacists in managing diabetic
patients.
Method: This is a narrative review of the evidence from the literature in order to answer the pres-
ent question of what is the evidence of the role of clinical pharmacists in managing diabetic patients.
We searched ﬁve databases including: the Cochrane library, MEDLINE, EMBASE, TRIP, and
Science Direct. We will also try to look for other potentially eligible trials or ancillary publications
by searching the reference lists of retrieved included trials, (systematic) reviews, meta-analyses and
health technology assessment reports. Outcomes included short-term and long-term measures.
Results: Final search revealed nine studies. They were heterogeneous in terms of interventions,
participants, settings and outcomes. Studies varied in their quality and/or reporting of their ﬁndings
conducted in several settings. Majority of the studies were conducted in Western countries, one in
Hong Kong and one in South India. In majority of the studies, pharmacists’ role was mainly to
specify all drug-related problems including poor drug compliance and side effects and communicat-
ing these to the physician. We found that those who received the pharmacist care had a statistically
signiﬁcant reduction in coronary heart disease, blood pressure, HA1c, quality of life and lipid
proﬁle.
442 S. Alhabib et al.Conclusion: Our review demonstrated the important role of clinical pharmacists in managing
diabetic patients at diverse settings worldwide. There is an urgent need to recognize and change reg-
ulations to allow shared practice agreements among physicians, pharmacists, and other allied health
professionals. These mutual agreements would allow more streamlined provision of health care
delivery from non-physician health professionals to participants with common health conditions.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Contents
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Diabetes mellitus is a rapidly growing disease world-wide that
is estimated to be present in 6.6% of the international popula-
tion and projected to increase by 7.8% in 2030 (Wild et al.,
2004). It is considered of clinical and public health signiﬁcance,
as it adversely affects personal health, health-related quality of
life, life expectancy and has signiﬁcant implications on the
health care system. Epidemiological evidence shows that
diabetes frequently results in severe complications, such as
cardiovascular disease, cerebro-vascular disease, micro-vascular
disorders (e.g. nephropathy, retinopathy, neuropathy, sexual
dysfunction) and diabetic foot disorders (ADA, 2009).
Treating diabetic patients is multifaceted in all aspects and
they require objectives and optimum information in order to
obtain the maximum beneﬁts of their treatment and avoid
complications. This is a collaborative process involving the
patient, physician, pharmacist and other health care profes-
sionals. Pharmacists are increasingly considered as a part of
the healthcare system whether in community pharmacies,
primary care centers, or hospitals (Ghani et al., 2010). The role
of pharmacists in several countries has expanded beyond
medication dispensing to a more active involvement of patient
management and follow up. The contribution of pharmacists
in the detection of drug complications, interactions or treat-
ment failures is of valuable information for physicians, who
may then, if they judge it convenient, introduce some changes
in the prescribed medication (Berenguer et al., 2004).
Recent and comprehensive evidence on levels and trends of
the effectiveness of clinical pharmacists in managing diabetes is
a critical input to more informed priority setting. It provides
an opportunity to quantify process of care against explicit
health targets whether local, national or global and to evaluate
whether programs are working or not. Quantiﬁcation acrosspopulations and overtime using diverse or even comparable
process and methods can also facilitate meaningful bench-
marking efforts. Regular and comprehensive updating of the
evidence or the role of clinical pharmacists in the control of
diabetes can also help in identifying new challenges as they
emerge. Hence, the aim of this review is to address and sum-
marize the effectiveness of clinical pharmacists in managing
diabetic patients.
2. Method
This is a narrative review of the evidence from the literature in
order to answer the present question of what is the evidence of
the role of clinical pharmacists in managing diabetic patients.
We searched ﬁve databases including: the Cochrane library,
MEDLINE, EMBASE, TRIP, and Science Direct. We also
searched databases of ongoing trials (clinicalTrials.gov/ and
controlled-trials.com). We will also try to look for other poten-
tially eligible trials or ancillary publications by searching the
reference lists of retrieved included trials, (systematic) reviews,
meta-analyses and health technology assessment reports.
Search terms used were MeSH and keywords with different
combinations of Boolean operators according to the database
but were comparable (see Appendix A for search terms). Out-
come measures included: glycemic control (HA1c), body mass
index (BMI), lipid proﬁles, medications adherence, quality of
life, mental health outcomes, utilization of health services,
adverse effects, and economic outcomes. Search was con-
ducted on April 2013 and updated on March 2014. Studies
included were: randomized controlled trials, cohort and case-
controlled studies, health technology report, meta-analysis
and systematic reviews. Types of participants included in this
review were pharmacist delivering services other than or in
addition to medications dispensed in different health settings.
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Search revealed 67 hits. Of these, 57 studies were excluded and
nine were retrieved as they fulﬁlled the inclusion criteria. They
were heterogeneous in terms of interventions, participants,
settings and outcomes (Table 1). Studies varied in their quality
and/or reporting of their ﬁndings conducted in several settings
including: primary care in the UK, managed care, family
practice in the US and Canada or elsewhere in the world
(Chan et al., 2012; Clifford et al., 2005; Cohen et al., 2011;
Pinto et al., 2012; Richmond et al., 2010; Sriram et al., 2011;
Li et al., 2010; Smith et al., 2013; Pande et al., 2013). They also
differed in the methods and instruments used to assess the
effectiveness and impacts of pharmaceutical care and/or
clinical pharmacists on the health outcomes of patients with
diabetes mellitus and/or multiple chronic diseases. Majority
of the studies were conducted in Western countries, one in
Hong Kong and one in South India. All the studies compared
the clinical pharmacist/pharmaceutical care (intervention) with
the usual care (control) diabetic patients received in the
correspondent health settings. In all the studies, follow-up of
patients ranged from 12 weeks to 2 years.
Chan and colleagues in Hong Kong conducted a random-
ized controlled trial (RCT) comparing regular drug-counseling
sessions performed by pharmacist in addition to routine
medical care compared to routine medical care in diabetic II
patients (Chan et al., 2012). They found that those who
received the pharmacist care had a statistically signiﬁcant
reduction in the coronary heart disease (CHD) risk compared
to those in the control group (1.64 ± 3.56%; n= 51 vs.
0.01 ± 3.08%; =54, P= .013), reduction in stroke
(1.06 ± 1.82% vs. 0.31 ± 2.51%, P= .002), decreased
hemoglobin A1c (1.57 ± 1.50% vs. 0.40 ± 1.19%,
P=<.001), and lowering of low-density-lipoprotein (LDL)
(0.36 ± 0.76 vs. 0.03 ± 0.74, P= .026). Although the
diastolic blood pressure was 4 times greater in the intervention
group, there was no signiﬁcant difference in blood pressure
between the intervention and control groups.
In Australia, the Fremantle diabetes study investigated the
effect of a pharmaceutical care (PC) program on vascular risk
factors in type II DM (Clifford et al., 2005). PC patients had
face-to-face goal-directed medication and lifestyle counseling
at baseline and at 6 and 12 months plus 6-weekly telephone
assessments and provision of other educational material. The
study revealed a signiﬁcant improvement in r HbA1c
(0.5% [95% CI 0.7 to 0.3] vs. 0 [0.2 to 0.2]) and
systolic (14 mmHg [19 to 9] vs. 7 [11 to 2]) and
diastolic (5 mmHg [8 to 3] vs. 2 [4 to 1]) blood
pressure (P= 0.043). Authors also showed that the improve-
ment in HbA1c persisted after adjustment for baseline value
and demographic and treatment-speciﬁc variables. Addition-
ally, there was a signiﬁcant reduction in 10-year estimated risk
of a ﬁrst CHD event in the intervention group (p=<0.01).
Moreover, in a randomized controlled trial in the US
(Rhode Island), researchers found that a pharmacist-led
shared medical management program signiﬁcantly improved
hypertension, hyperglycemia and lipidemia in patients with
diabetes than those followed up by the usual standard primary
care physicians (Cohen et al., 2011).
In a longitudinal prospective study conducted in the US,
pharmacist led care resulted in signiﬁcant improvement inmean HA1C concentration at 12 months, a decrease in mean
systolic and diastolic blood pressure, and a decrease in alcohol
and smoking consumption and an increase in exercise (Pinto
et al., 2012). However, Richmond and colleagues in the UK
also conducted a study at primary care centers to estimate
the effectiveness of pharmaceutical care for older people,
shared between GPs and community pharmacists in the UK,
relative to usual care (Richmond et al., 2010). The results
did not signiﬁcantly change the appropriateness of prescribing
or quality of life (QOL) in older patients.
QOL is another measure that interested researchers to
examine in diabetic patients. Sriram et al. in India, conducted
a prospective study to evaluate the impact of pharmaceutical
care on QOL in patients with type 2 diabetes mellitus
(Sriram et al., 2011). They showed a signiﬁcant improvement
in the intervention group (p< 0.01) using Bradley’s question-
naire, the Audit of Diabetes Dependent Quality of Life
(ADDQOL). Patients were satisﬁed with their treatment, felt
slightly affected due to their disease, and rarely worried about
the negative consequences of their diabetes. Furthermore,
several clinical measures correlated well with the quality of life.
Patients who were more satisﬁed with their current treatment
tend to have better glycemic and blood pressure control.
Also, in a meta-analysis, pharmaceutical care (PC) pro-
grams delivered separately or in combination by pharmacists
and other health professionals can lead to an improvement
in glycemic control compared to the usual care. The research-
ers also recommended that the incorporation of PC programs
into disease management should be strongly considered
(Li et al., 2010).
Nichols-English emphasized that a major role of pharma-
cists in collaborative care is to assist patients to adhere to their
self-care and therapeutic regimens (Nichols-English et al.,
2002). An optimal role in assisting other primary care
providers is to simplify, clarify and reinforce the prescribed
therapeutic and self management regimens.
In a recent Cochrane systematic review, authors found that
in the care of elderly with poly-pharmacy, pharmaceutical care
appears beneﬁcial in terms of reducing inappropriate prescrib-
ing and medication-related problems (Patterson et al., 2012).
Additionally, a review showed that pharmacist intervention
in type 2 Diabetes Mellitus patients was successful in leading
to reductions in mortality, morbidity and cost of treatment
(O’Donovan et al., 2011).
4. Discussion
This review highlighted the value of the clinical pharmacist/
pharmacist care program that targeted immediate and long-
term risk factors associated with DM. This extended across
multiple health care settings and cultures worldwide. In the
majority of the studies, pharmacists’ role was mainly to specify
all drug-related problems including poor drug compliance and
side effects and communicating these to the physician. Such
communication (verbal and/or written) is crucial in building
professional working relationships necessary to ensure optimal
patient care. However, pharmacists’ involvement is not meant
to replace the formal DM education or physician direct care,
nevertheless, the program provides a useful supplement or
enhancement to the care of diabetic patients. This is especially
important to be emphasized, where there might be a culture of
Table 1 Summary of included studies.
Study Country Intervention Control Results
Chan et al. (20120: A pharmacist
care program: Positive impact on
cardiac risk in patients with
type 2 diabetes
Hong Kong RCT: regular drug-counseling
sessions with pharmacists in
addition to routine medical care
Routine
medical care
Intervention group had a
statistically signiﬁcant reduction
in CHD risk compared to those
in the control group, P= 0.013
ﬂstroke (p= 0.002), ﬂHA1c
(p< 0.001), ﬂ LDL (p= 0.03)
Cliﬀord et al. (2005): eﬀect of a
pharmaceutical care program on
vascular risk factors in type 2
diabetes
Australia RCT: had face-to-face goal-directed
medication and lifestyle counseling at
baseline and at 6 and 12 months plus
6-weekly telephone assessments and
provision of other educational
material
Regular care Signiﬁcant improvement in BMI,
FBS, HA1C, BP, Lipid proﬁles
(p= 0.001–0.04)
Cohen et al. (2011): Pharmacist-
led shared medical appointments
for multiple cardiovascular risk
reductions in patients with type 2
diabetes
US RCT: 1 h session every month for








ﬂTotal cholesterol, ﬂ BP, ﬂHA1C
(p= 0.015). However, no
change in smoking rate and QOL
Pinto et al. (2012): Evaluation
of outcomes of a medication
therapy management program
for patients with diabetes
US Prospective longitudinal study:
counseling sessions
No control ﬂHA1C, ﬂ BP (p= 0.02)





UK Prospective follow up: shared




Did not signiﬁcantly change the
appropriateness of prescribing or
quality of life in older patients
Sriram et al. (2011): Impact of
pharmaceutical care on quality of
life in patients with type 2
diabetes mellitus
South India RCT: diabetes education, medication
counseling, instructions on lifestyle
that needed modiﬁcations (necessary
for better drug function) and dietary
regulations regarding their prescribed
drugs
Usual care Improvement in the quality of
life score, p< 0.01
Li et al. (2010): Eﬀect of
pharmaceutical care programs
on glycemic control in patients
with diabetes mellitus: a
meta-analysis of randomized
controlled trials






Usual care PC intervention groups had
signiﬁcant ﬂ in HA1C levels
(p< 0.01, 95% CI 1.03 to
0.34)
Smith et al. (2013): Interventions
for improving outcomes in
patients with multimorbidity in
primary care and community
settings
Cochrane review Ten studies, low risk of bias, complex
interventions; multiple elements,
multidisciplinary team work,
involving pharmacist in many
Usual care Mixed eﬀects; improve
prescribing, medication
adherence, predominant change
to the organization of care
delivery, potential signiﬁcant cost
saving
Pande et al. (2013): The eﬀect
of pharmacist-provided
non-dispensing services on
patient outcomes, health service
utilization and costs in low- and
middle-income countries
Cochrane review 12 studies, pharmacist-provided
services
Usual care Reduction in health service
utilization, small improvement in
clinical outcomes, improvement
in quality of life
444 S. Alhabib et al.sensitivity from other health professionals (e.g. physicians) and
the fear of taking over responsibilities by the pharmacists (per-
sonal view).
Pharmacist contributed to beneﬁcial reductions in modiﬁ-
able vascular risk factors, most notably glycemic control and
blood pressure. In the case of glycemic control, the improve-
ment continued after adjustment for key demographic vari-
ables and intensiﬁcation of pharmacotherapy, suggesting that
the participation of the pharmacists had a positive impact on
medication adherence and other factors that are important indiabetes self-care. Furthermore, the PC program was associ-
ated with a signiﬁcant reduction in the estimated 10-year risk
of CHD in a primary prevention setting.
Another study that was conducted in Australia, a 12 month
program in type 2 diabetes that was managed by pharmaceu-
tical care reduced HA1C and blood pressure signiﬁcantly com-
pared to those who were managed by clinicians only (Clifford
et al., 2005). However, the patients in the intervention group
had longer diabetes duration than the control which might
explain the observed beneﬁts.
Clinical pharmacists role in management of diabetes 445There are differences between studies and this might com-
promise the generalizability of the ﬁndings. For example, the
equation used for the CHD risk score in one study was tailored
for a speciﬁc population (Hong Kong); therefore, ﬁndings of
their study may not apply to other ethnic groups as they are
correctly highlighted. In addition, such a program might be
considered a success as every 0.5% reduction in HbA1c might
lead to a 7% decrease in myocardial infarction and a 12%
decrease in the risk of stroke (Stratton et al., 2000). The reduc-
tion in systolic blood pressure might explain the signiﬁcant
reduction in the rate of stroke. This is very essential to address
as cardiovascular disease is the main cause of death in patients
with diabetes mellitus and is largely preventable by simulta-
neous control of cardiovascular risk factors (Leonard, 2003;
Gæde et al., 2008). Moreover, this is consistent with the cur-
rent guidelines for comprehensive diabetes management that
ensures intensive pharmacologic and behavioral interventions
for the treatment of hypertension, hyperlipidemia, hyperglyce-
mia, and tobacco cessation (Association, 2010).
Although all the studies included showed some beneﬁts of
the clinical pharmacists, only one that was conducted in the
UK showed no evidence of effectiveness. The researchers
explained that the lack of positive evidence stems from
researchers’ experience that pharmaceutical care is difﬁcult to
implement fully in the community. Furthermore, they
addressed that self-selection of the included practices may have
excluded those practices associated with poorer standards of
prescribing, which could have affected the results of their
study. However, taken together, these results suggest that the
success of PC depends on the combination of patient charac-
teristics, context, settings, and duration.
This review has some limitations. Some studies might be
missed and not included as the search terms and/or database
search was not meant to be conducted for a systematic review
rather for the purpose of a narrative review. Additionally,
search was limited to studies published in English and, hence,
studies conducted in other languages might be overlooked.
Furthermore, some of the results were based on patient self-
reporting, which might likely overestimate, for example, the
adherence. Therefore, we tried to limit these probable biases
by focusing on objective measures as endpoints. Also, blinding
in these studies was not possible and this might impact the
level of care and education provided to patients under the
usual care arm as a control. Moreover, generalizability of
our ﬁndings might not be extrapolated to different settings
and context. This is due to variations in health system set-up
and cost implications in different countries.
The strengths of this review lie in its comprehensive search
and summarization of results from different countries in differ-
ent health care settings and various cultures. This review moti-
vated the effort to conduct a more systematic review with focus
on subgroup analysis to address different beneﬁts and level of
evidence in terms of settings, culture, health care system
arrangement, gender, and age groups.5. Conclusion
Our review demonstrated the important role of clinical
pharmacists in managing diabetic patients at diverse settings
in many countries worldwide. This was established for both
the immediate care of such patients and their associated riskfactors targeting holistically their care in partnership with
the physician and other health care professional team. Further-
more, pharmacist contributed to medication adherence,
knowledge and understanding of diabetic patients at multiple
levels. Therefore, they are very valuable to the care of such
patients and should be considered and involved in other health
care problem management especially in patients with chronic
diseases.
Moreover, our review revealed that the pharmacist-led
group intervention program was an efﬁcacious and sustainable
collaborative care approach to manage diabetes, educate
patients to improve self-care behaviors, and reduce associated
cardiovascular risk.6. Implications
This review has several implications for the practice and future
research efforts. Economic analysis was not performed in the
studies included in this review. Therefore, the need for such
analysis is imperative. This is because we think that the stan-
dard model of diabetes care may not be practical in the future
with the continued increase in diabetes diagnoses, decrease in
primary care physicians, and decreasing funds for medical
treatment, especially in developing countries. This is evidenced
by all the aforementioned studies, that pharmacists are crucial
members of inter-professional teams and will continue to be in
the light of the need for changes and innovations we need in
the current health care services.
Furthermore, there is an urgent need to recognize and
change regulations to allow shared practice agreements among
physicians, pharmacists, and other allied health professionals
with pharmaco-therapeutic co-management. These mutual
agreements would allow more streamlined provision of health
care delivery from non-physician health professionals to par-
ticipants with common health conditions, such as diabetes
and cardiovascular risks.
Additionally, it would be interesting to explore the gender
differences in diabetic patients. Studies have shown that men
may not have as much progress in self-care behavior as women
due to differences in the social cognitive determinants between
sexes (Hankonen et al., 2010). Therefore, we encourage inves-
tigating such differences in future research as this might help in
focusing the management and resource distribution to the
most needed population.
Moreover, there is a need to extend the duration of future
studies into longer period in order to evaluate the effectiveness
of clinical pharmacists not only on short morbidity outcome,
but also on mortality in the long-term scale.
Clinicians’ perceptions and views about the role of clinical
pharmacists need also to be explored in future research efforts
in order to obtain various role perceptions that are likely to
result in barriers to pharmacists expanding their roles in differ-
ent health care settings.
Appendix A. Search strategy
1. Pharmaceutical Care.mp. [mp = title, abstract, original
title, name of substance word, subject heading word,
keyword heading word, protocol supplementary concept
word, rare disease supplementary concept word, unique
identiﬁer] (1231).
446 S. Alhabib et al.2. Clinical pharmacists.mp. [mp = title, abstract, original
title, name of substance word, subject heading word,
keyword heading word, protocol supplementary concept
word, rare disease supplementary concept word, unique
identiﬁer] (686).
3. Pharmacist.mp. [mp= title, abstract, original title, name of
substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identiﬁer] (7889).
4. 1 or 2 or 3 (8717).
5. Family physician.mp. [mp = title, abstract, original
title, name of substance word, subject heading word,
keyword heading word, protocol supplementary concept
word, rare disease supplementary concept word, unique
identiﬁer] (3395).
6. Primary care.mp. [mp= title, abstract, original title, name
of substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identiﬁer] (65516).
7. General practitioner.mp. [mp = title, abstract, original
title, name of substance word, subject heading word,
keyword heading word, protocol supplementary concept
word, rare disease supplementary concept word, unique
identiﬁer] (13469).
8. 5 or 6 or 7 (80143).
9. Diabetes.mp. [mp = title, abstract, original title, name
of substance word, subject heading word, keyword
heading word, protocol supplementary concept word,
rare disease supplementary concept word, unique
identiﬁer] (385066).
10. Diabetic patients.mp. [mp = title, abstract, original
title, name of substance word, subject heading word,
keyword heading word, protocol supplementary concept
word, rare disease supplementary concept word, unique
identiﬁer] (41614).
11. 9 or 10 (390626).
12. Control.mp. [mp= title, abstract, original title, name of
substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identiﬁer] (1864991).
13. Effectiveness.mp. [mp= title, abstract, original title, name
of substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identiﬁer] (248213).
14. Impact.mp. [mp = title, abstract, original title, name of
substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare dis-
ease supplementary concept word, unique identiﬁer]
(448593).
15. 12 or 13 or 14 (2430258).
16. 4 and 8 and 11 and 15 (49).References
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